Track topics on Twitter Track topics that are important to you
(JCI Journals) Immunotherapies targeting the immune checkpoint receptor PD-1 and its ligand, PD-L1, have been shown to successfully activate T cells against certain cancers, but their efficacy varies between cancer types and between individual patients. An article published in this week's issue of the JCI describes an important role for natural killer in PD-1/PD-L1-targeting immunotherapy, a discovery that may help scientists develop more powerful immune-targeting anti-cancer treatments.NEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...